High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.
COVID-19
ELISA
LuLISA
SARS-CoV-2
bioluminescence
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
07
11
2020
revised:
07
11
2020
accepted:
30
11
2020
pubmed:
2
12
2020
medline:
25
2
2021
entrez:
1
12
2020
Statut:
ppublish
Résumé
Although the COVID-19 pandemic peaked in March/April 2020 in France, the prevalence of infection is barely known. Using high-throughput methods, we assessed herein the serological response against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) of 1847 participants working in three sites of an institution in Paris conurbation. In May-July 2020, 11% (95% confidence interval [CI]: 9.7-12.6) of serums were positive for IgG against the SARS-CoV-2 N and S proteins, and 9.5% (95% CI: 8.2-11.0) were neutralizer in pseudo-typed virus assays. The prevalence of seroconversion was 11.6% (95% CI: 10.2-13.2) when considering positivity in at least one assay. In 5% of RT-qPCR positive individuals, no systemic IgGs were detected. Among immune individuals, 21% had been asymptomatic. Anosmia (loss of smell) and ageusia (loss of taste) occurred in 52% of the IgG-positive individuals and in 3% of the negative ones. In contrast, 30% of the anosmia-ageusia cases were seronegative, suggesting that the true prevalence of infection may have reached 16.6%. In sera obtained 4-8 weeks after the first sampling, anti-N and anti-S IgG titers and neutralization activity in pseudo-virus assay declined by 31%, 17%, and 53%, resulting thus in half-life of 35, 87, and 28 days, respectively. The population studied is representative of active workers in Paris. The short lifespan of the serological systemic responses suggests an underestimation of the true prevalence of infection.
Identifiants
pubmed: 33259646
doi: 10.1002/eji.202049058
pmc: PMC7753614
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
180-190Informations de copyright
© 2020 Wiley-VCH GmbH.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
Lancet Infect Dis. 2021 Apr;21(4):e69-e70
pubmed: 32679085
Sci Rep. 2021 Jun 21;11(1):12930
pubmed: 34155259
Sci Transl Med. 2020 Sep 2;12(559):
pubmed: 32817357
Allergy. 2020 Nov;75(11):2952-2956
pubmed: 32407549
Nat Med. 2020 Aug;26(8):1196-1199
pubmed: 32641783
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Clin Chem Lab Med. 2020 Aug 26;58(12):2107-2111
pubmed: 32845861
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Nat Med. 2020 Aug;26(8):1193-1195
pubmed: 32504052
N Engl J Med. 2020 Oct 29;383(18):e101
pubmed: 32897661
JAMA Intern Med. 2020 Jul 21;:
pubmed: 32692365
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Blood Transfus. 2021 May;19(3):181-189
pubmed: 33539289
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Nat Commun. 2021 May 21;12(1):3025
pubmed: 34021152
Eur J Immunol. 2020 Dec;50(12):2025-2040
pubmed: 33084029
Chemistry. 2020 Jan 16;26(4):948-958
pubmed: 31765054
Ann Epidemiol. 2020 Aug;48:23-29.e4
pubmed: 32648546
J Infect Dis. 2020 Nov 13;222(12):1955-1959
pubmed: 32906151
Infect Control Hosp Epidemiol. 2021 Feb;42(2):212-214
pubmed: 32746953
Mol Ther. 2007 Jun;15(6):1203-10
pubmed: 17375069
J Infect. 2021 May;82(5):186-230
pubmed: 33545165
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
Org Biomol Chem. 2019 Apr 10;17(15):3709-3713
pubmed: 30882838
Lancet Microbe. 2021 Feb;2(2):e60-e69
pubmed: 33521709
Biochem Biophys Res Commun. 2014 Feb 28;445(1):157-62
pubmed: 24491536
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310